Clinical trial · Interventional
Transcranial Direct Current Stimulation for Cancer-related Cognitive Impairment in Breast Cancer Survivors
Efficacy and Mechanisms of Transcranial Direct Current Stimulation (tDCS) on Cancer-Related Cognitive Impairment(CRCI) in Breast Cancer Survivors: A Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the efficacy of transcranial direct current stimulation (tDCS) in improving cancer-related cognitive impairment (CRCI) in breast cancer survivors. Participants will be randomly assigned to receive active or sham stimulation over the prefrontal cortex. Cognitive outcomes will be assessed using standardized neuropsychological tests and self-reported measures. Functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) will be used to explore neural correlates of intervention effects.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Survivor | — | UNRESOLVED | — |
| Cognitive Impairment | — | UNRESOLVED | — |
| Transcranial Direct Current Stimulation (tDCS) | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anodal transcranial direct current stimulation | Device | — | UNRESOLVED |
| Sham transcranial direct current stimulation | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Anodal tDCS
- description
- Participants will receive active tDCS for 20 minutes daily, 5 sessions per week, over 4 consecutive weeks (total 20 sessions). The anodal electrode was placed on the DLPFC (F3) surrounded by four cathodes with 1-cm diameter (FCz, AFz, F7, and C5). The stimulation direct current magnitude was set at 2 mA with a 30-s immediate decline at the beginning and end of each phase.
- interventionNames
- Device: Anodal transcranial direct current stimulation
- type
- SHAM_COMPARATOR
- label
- sham stimulation
- description
- Participants will receive sham stimulation for 20 minutes daily, 5 sessions per week, over 4 consecutive weeks (total 20 sessions). In the sham condition, a 30-s rising current until 2 mA is reached, with a 30-s decline immediately at the beginning and end of the stimulation section.
- interventionNames
- Device: Sham transcranial direct current stimulation
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female breast cancer survivors aged 18-65 years. 2. Initially diagnosed with stage I-III non-metastatic breast cancer. 3. Between 6 months and 5 years after completion of initial curative surgery +/- radiation/chemotherapy. 4. allowed to be on endocrine therapy and/or anti-HER2 targeted therapy. 5. Self-reported cognitive complaints following cancer treatment. 6. Right-handedness (for standardized tDCS targeting) 7. Education level ≥ 6 years 8. Able and willing to undergo all study procedures (neuropsychological testing, MRI, EEG, etc.) and to provide written informed consent Exclusion Criteria: 1. Contraindications to MRI or EEG (e.g., pacemaker, metallic implants, claustrophobia). 2. Active neurological/psychiatric disorders (e.g., major depressive disorder, bipolar disorder, schizophrenia, Parkinson's disease, post-stroke sequelae) 3. Concurrent use of cognition-enhancing medications (e.g., donepezil, memantine) 4. Severe somatic diseases (cardiac/hepatic/renal insufficiency) 5. Pregnant or breastfeeding 6. Concurrent participation in another interventional clinical trial
References
Publications (0)
Data not yet available